A diagnosis of AD currently relies on positron emission tomography (PET) imaging or measurement of amyloid beta (Aβ) and phosphorylated Tau (p-tau) in cerebrospinal fluid (CSF) (3, 4). Here, MAPT is linked to Alzheimer disease.